Bardet–Biedl syndrome: Difference between revisions
No edit summary |
No edit summary |
||
| Line 72: | Line 72: | ||
==Management== |
==Management== |
||
There is currently no specific treatment but it is important that an experienced multidisciplinary team manages patients with adequate supportive treatments.<ref> |
There is currently no specific treatment but it is important that an experienced multidisciplinary team manages patients with adequate supportive treatments.<ref>{{cite journal | vauthors = Melluso A, Secondulfo F, Capolongo G, Capasso G, Zacchia M | display-authors = | title = Bardet-Biedl Syndrome: Current Perspectives and Clinical Outlook | journal = Therapeutics and Clinical Risk Management | volume = 2023:19 | issue = | pages = 115—132 | date = January 2023| pmid = 36741589 | pmc = 9896974 | doi = 10.2147/TCRM.S338653 }}</ref> |
||
==Eponym== |
==Eponym== |
||
Revision as of 13:57, 6 February 2023
| Bardet–Biedl syndrome | |
|---|---|
| Other names | Biedl-Bardet Syndrome [1] |
 | |
| This condition is often inherited via autosomal recessive manner (including digenic recessive); but epigenetic phennomena also cause some of the variation seen in BBS | |
| Specialty | Medical genetics  |
Bardet–Biedl syndrome (BBS) is a ciliopathic human genetic disorder that produces many effects and affects many body systems. It is characterized by rod/cone dystrophy, polydactyly, central obesity, hypogonadism, and kidney dysfunction in some cases.[2] Historically, slower mental processing has also been considered a principal symptom but is now not regarded as such.
Signs and symptoms
Bardet–Biedl syndrome is a pleiotropic disorder with variable expressivity and a wide range of clinical variability observed both within and between families. The most common clinical features are rod–cone dystrophy, with childhood-onset night-blindness followed by increasing visual loss; postaxial polydactyly; truncal obesity that manifests during infancy and remains problematic throughout adulthood; varying degrees of learning disabilities; male hypogenitalism and complex female genitourinary malformations; and renal dysfunction, a major cause of morbidity and mortality.[3]
There is a wide range of secondary features that are sometimes associated with BBS[4]: 147–148 including[4]: 153–154
- Strabismus, cataracts, astigmatism, pigmentary retinopathy, poor visual acuity, low vision, and/or blindness caused by an impaired photoreceptor transport mechanism in the retina.[5]
- "Brachydactyly, syndactyly of both the hands and feet is common, as is partial syndactyl (most usually between the second and third toes)"
- Polyuria/polydipsia (nephrogenic diabetes insipidus)
- Ataxia/poor coordination/imbalance
- Mild hypertonia (especially lower limbs)
- Diabetes mellitus
- Hepatic involvement
- Anosmia
- Auditory deficiencies
- Hirschsprung disease and subsequent bowel obstruction has been described.[6]
- Hypertrophy of interventricular septum and left ventricle and dilated cardiomyopathy.
- Hypogonadism, kidney failure, urogenital sinuses, ectopic urethra, uterus duplex, septate vagina, and hypoplasia of the uterus, ovaries, and fallopian tubes
- Speech disorder/delay
- Developmental delay, especially of fine and gross motor skills[citation needed]
Relation to other rare genetic disorders
Findings in genetic research published in 2006 have suggested that a large number of genetic disorders, both genetic syndromes and genetic diseases, that were not previously identified in the medical literature as related, may be, in fact, highly related in the genetypical root cause of the widely varying, phenotypically observed disorders. BBS is one such syndrome that has now been identified to be caused by defects in the cellular ciliary structure. Thus, BBS is a ciliopathy. Other known ciliopathies include primary ciliary dyskinesia, polycystic kidney and liver disease, nephronophthisis, Alström syndrome, Meckel–Gruber syndrome and some forms of retinal degeneration.[7]
Pathophysiology
The detailed biochemical mechanism that leads to BBS is still unclear.[citation needed]
The gene products encoded by these BBS genes, called BBS proteins, are located in the basal body and cilia of the cell.[8]
Using the round worm C. elegans as a model system, biologists found that BBS proteins are involved in a process called intraflagellar transport (IFT), a bi-directional transportation activity within the cilia along the long axis of the ciliary shaft that is essential for ciliogenesis and the maintenance of cilia.[9] Recent biochemical analysis of human BBS proteins revealed that BBS proteins are assembled into a multiple protein complex, called "BBSome". BBSome is proposed to be responsible for transporting intracellular vesicles to the base of the cilia and to play an important role in the ciliary function.[citation needed]
Since abnormalities of cilia are known to be related to a wide range of disease symptoms including those commonly seen in BBS patients, it is now widely accepted that mutated BBS genes affect normal cilia function, which, in turn, causes BBS.[citation needed]
A theory that photoreceptor cells are nourished by the IFT of retinal cilia now offers a potential explanation for the retinal dystrophy common in BBS patients after their early years of life.[10][11]
Genes involved include:
- BBsome: BBS1, BBS2, ARL6/BBS3, BBS4, BBS5, BBS7, TTC8/BBS8, BBS10, TRIM32/BBS11 BBS12, CCDC28B, CEP290, TMEM67, MKS1, MKKS[12]
- chaperone: BBS6[citation needed]
Diagnosis
The diagnosis of BBS is established by clinical findings and family history. Molecular genetic testing can be used to confirm the diagnosis. Multigene panels offer the most effective approach in achieving molecular confirmation of BBS.[citation needed]
Management
There is currently no specific treatment but it is important that an experienced multidisciplinary team manages patients with adequate supportive treatments.[13]
Eponym
The syndrome is named after Georges Bardet and Arthur Biedl.[14][why?] The first known case was reported by Laurence and Moon in 1866 at the Ophthalmic Hospital in South London. Laurence–Moon–Biedl–Bardet syndrome is no longer considered as valid terms in that patients of Laurence and Moon had paraplegia but no polydactyly or obesity, which are the key elements of the Bardet–Biedl syndrome. Laurence–Moon syndrome is usually considered a separate entity. However, some recent research suggests that the two conditions may not be distinct.[15]
As of 2012[update], 14[12] (or 15)[16] different BBS genes had been identified.
References
- ^ "Bardet-Biedl syndrome | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program". rarediseases.info.nih.gov. Retrieved 13 August 2019.
- ^ Beales PL, Elcioglu N, Woolf AS, Parker D, Flinter FA (June 1999). "New criteria for improved diagnosis of Bardet-Biedl syndrome: results of a population survey". Journal of Medical Genetics. 36 (6): 437–446. doi:10.1136/jmg.36.6.437. PMC 1734378. PMID 10874630. Archived from the original on 2008-03-14. Retrieved 2007-10-11.
- ^ Rissardo JP, Caprara AL (2021). "Laurence-moon-biedl-bardet syndrome: An overview". Taiwan Journal of Ophthalmology. 11 (1): 108–109. doi:10.4103/tjo.tjo_2_20. PMC 7971431. PMID 33767966.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ a b Ross A, Beales PL, Hill J (2008). The Clinical, Molecular, and Functional Genetics of Bardet–Biedl Syndrome, in Genetics of Obesity Syndromes. Oxford University Press. doi:10.1093/med/9780195300161.001.0001. ISBN 978-0-19-530016-1. Retrieved 2009-07-01.
- ^ Abd-El-Barr MM, Sykoudis K, Andrabi S, Eichers ER, Pennesi ME, Tan PL, et al. (December 2007). "Impaired photoreceptor protein transport and synaptic transmission in a mouse model of Bardet-Biedl syndrome". Vision Research. 47 (27): 3394–3407. doi:10.1016/j.visres.2007.09.016. PMC 2661240. PMID 18022666.
- ^ Ramji AN. Sigmoid volvulus in bardet-biedl syndrome: serendipity or a new association? Int Surg J 2019;6:1388-91.
- ^ Badano JL, Mitsuma N, Beales PL, Katsanis N (2006). "The ciliopathies: an emerging class of human genetic disorders". Annual Review of Genomics and Human Genetics. 7: 125–148. doi:10.1146/annurev.genom.7.080505.115610. PMID 16722803. S2CID 40223129.
- ^ Ansley SJ, Badano JL, Blacque OE, Hill J, Hoskins BE, Leitch CC, et al. (October 2003). "Basal body dysfunction is a likely cause of pleiotropic Bardet-Biedl syndrome". Nature. 425 (6958): 628–633. Bibcode:2003Natur.425..628A. doi:10.1038/nature02030. PMID 14520415. S2CID 4310157.
- ^ Blacque OE, Reardon MJ, Li C, McCarthy J, Mahjoub MR, Ansley SJ, et al. (July 2004). "Loss of C. elegans BBS-7 and BBS-8 protein function results in cilia defects and compromised intraflagellar transport". Genes & Development. 18 (13): 1630–1642. doi:10.1101/gad.1194004. PMC 443524. PMID 15231740.
- ^ Sedmak T, Wolfrum U (April 2010). "Intraflagellar transport molecules in ciliary and nonciliary cells of the retina". The Journal of Cell Biology. 189 (1): 171–186. doi:10.1083/jcb.200911095. PMC 2854383. PMID 20368623.
- ^ Orozco JT, Wedaman KP, Signor D, Brown H, Rose L, Scholey JM (April 1999). "Movement of motor and cargo along cilia". Nature. 398 (6729): 674. Bibcode:1999Natur.398..674O. doi:10.1038/19448. PMID 10227290. S2CID 4414550.
- ^ a b Hamosh A (2012-11-02). "OMIM entry #209900 Bardet-Biedl Syndrome; BBS". Online Mendelian Inheritance in Man. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine. Archived from the original on 2016-05-17. Retrieved 2013-09-04.
- ^ Melluso A, Secondulfo F, Capolongo G, Capasso G, Zacchia M (January 2023). "Bardet-Biedl Syndrome: Current Perspectives and Clinical Outlook". Therapeutics and Clinical Risk Management. 2023:19: 115–132. doi:10.2147/TCRM.S338653. PMC 9896974. PMID 36741589.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ synd/3745 at Who Named It?
- ^ Moore SJ, Green JS, Fan Y, Bhogal AK, Dicks E, Fernandez BA, et al. (February 2005). "Clinical and genetic epidemiology of Bardet-Biedl syndrome in Newfoundland: a 22-year prospective, population-based, cohort study". American Journal of Medical Genetics. Part A. 132A (4): 352–360. doi:10.1002/ajmg.a.30406. PMC 3295827. PMID 15637713.
- ^ Hereditary Retinopathies: Progress in Development of Genetic and Molecular Therapies. Springer. 2012. p. 15. ISBN 9781461444992. Retrieved 2013-09-04.